Bittersweet Sugars: How Unusual Glycan Structures May Connect Epithelial-to-Mesenchymal Transition and Multidrug Resistance in Cancer.
cancer
epithelial–mesenchymal transition process
glycoconjugates
glycosyltransferases
multidrug resistance phenotype
Journal
Medicines (Basel, Switzerland)
ISSN: 2305-6320
Titre abrégé: Medicines (Basel)
Pays: Switzerland
ID NLM: 101671069
Informations de publication
Date de publication:
14 Jun 2023
14 Jun 2023
Historique:
received:
02
05
2023
revised:
04
06
2023
accepted:
09
06
2023
medline:
27
6
2023
pubmed:
27
6
2023
entrez:
27
6
2023
Statut:
epublish
Résumé
Cancer cells are characterized by metabolic reprogramming, which enables their survival in of-ten inhospitable conditions. A very well-documented example that has gained attraction in re-cent years and is already considered a hallmark of transformed cells is the reprogramming of carbohydrate metabolism. Such a feature, in association with the differential expression of en-zymes involved in the biosynthesis of glycoconjugates, generically known as glycosyltransfer-ases, contributes to the expression of structurally atypical glycans when compared to those ex-pressed in healthy tissues. The latest studies have demonstrated that glycophenotypic alterations are capable of modulating multifactorial events essential for the development and/or progres-sion of the disease. Herein, we will address the importance of glycobiology in modern medi-cine, focusing on the ability of unusual/truncated
Identifiants
pubmed: 37367731
pii: medicines10060036
doi: 10.3390/medicines10060036
pmc: PMC10305436
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Glycoconj J. 2001 Nov-Dec;18(11-12):859-65
pubmed: 12820719
Matrix Biol. 2023 Apr;118:47-68
pubmed: 36882122
Int J Oncol. 2014 Apr;44(4):1376-84
pubmed: 24452447
Front Oncol. 2016 Jun 22;6:158
pubmed: 27446804
J Biol Chem. 1989 Jun 25;264(18):10472-6
pubmed: 2471705
Biochim Biophys Acta Rev Cancer. 2023 May;1878(3):188889
pubmed: 37001617
Cancer Lett. 2007 May 8;249(2):157-70
pubmed: 16965854
Biomed Res Int. 2018 Jun 21;2018:9532389
pubmed: 30035127
Int Immunopharmacol. 2020 Aug;85:106631
pubmed: 32470879
Biochim Biophys Acta. 1999 Oct 8;1455(2-3):287-300
pubmed: 10571019
APMIS. 1992 Sep;100(9):817-26
pubmed: 1389100
Glycobiology. 2022 Jun 13;32(7):556-579
pubmed: 35312770
J Cell Mol Med. 2019 Mar;23(3):2083-2092
pubmed: 30637914
Nat Commun. 2021 Feb 24;12(1):1270
pubmed: 33627655
Cancer Res. 1990 Mar 1;50(5):1608-12
pubmed: 2406016
Transl Oncol. 2018 Jun;11(3):786-793
pubmed: 29702465
Methods Mol Biol. 2022;2370:301-313
pubmed: 34611876
J Cell Mol Med. 2019 Oct;23(10):6885-6896
pubmed: 31389667
Onco Targets Ther. 2019 Apr 18;12:3051-3063
pubmed: 31114248
Nanomedicine. 2017 Feb;13(2):713-722
pubmed: 27769887
Cancer Lett. 2008 Mar 8;261(1):108-19
pubmed: 18171600
J Mol Biol. 2016 Aug 14;428(16):3166-3182
pubmed: 27040397
Tumour Biol. 2020 Sep;42(9):1010428320957506
pubmed: 32914709
Nat Immunol. 2016 Nov;17(11):1273-1281
pubmed: 27595232
J Biol Chem. 2009 Jan 2;284(1):245-253
pubmed: 19010789
Mol Carcinog. 2015 Oct;54(10):1159-71
pubmed: 24962947
Gland Surg. 2021 Jul;10(7):2159-2169
pubmed: 34422587
Proc Natl Acad Sci U S A. 1985 Oct;82(19):6517-21
pubmed: 2995969
Vital Health Stat 2. 1987 Aug;(105):1-45
pubmed: 3686833
Medicines (Basel). 2022 May 24;9(6):
pubmed: 35736247
Int J Mol Sci. 2016 Feb 24;17(3):275
pubmed: 26927062
Cancer Cell. 2019 Jul 8;36(1):6-16
pubmed: 31287993
J Biomed Sci. 2020 Jul 3;27(1):77
pubmed: 32620165
Mol Cancer. 2015 May 29;14:109
pubmed: 26021314
Talanta. 2018 Jul 1;184:347-355
pubmed: 29674052
Blood Rev. 2015 Jul;29(4):269-79
pubmed: 25636501
Glycobiology. 2020 Apr 20;30(5):312-324
pubmed: 31868214
Glycoconj J. 2022 Apr;39(2):247-259
pubmed: 35156157
Nat Rev Nephrol. 2019 Jun;15(6):346-366
pubmed: 30858582
FEBS Lett. 2012 Jun 21;586(13):1813-20
pubmed: 22641031
Br J Cancer. 1994 Dec;70(6):1272-5
pubmed: 7981088
Medicines (Basel). 2022 Jun 16;9(6):
pubmed: 35736250
Cell Biol Int. 2020 Sep;44(9):1840-1849
pubmed: 32437085
Front Oncol. 2020 Feb 25;10:188
pubmed: 32161718
Oncol Rep. 1999 Mar-Apr;6(2):341-4
pubmed: 10023001
Cancer Res. 2008 Mar 15;68(6):1636-46
pubmed: 18339842
Front Immunol. 2022 Oct 20;13:973993
pubmed: 36341438
Proc Natl Acad Sci U S A. 2011 Oct 25;108(43):17690-5
pubmed: 22006308
HLA. 2016 Dec;88(6):275-286
pubmed: 27679419
Lab Invest. 2013 Jul;93(7):844-54
pubmed: 23752129
Front Oncol. 2014 Mar 25;4:59
pubmed: 24724053
Life (Basel). 2022 Jan 25;12(2):
pubmed: 35207462
Biotechnol Adv. 2023 Jul-Aug;65:108144
pubmed: 37028466
Anticancer Agents Med Chem. 2008 Jan;8(1):92-121
pubmed: 18220509
Eur J Immunol. 2022 Jun;52(6):946-957
pubmed: 35307819
Cancer Res. 1985 Jun;45(6):2405-14
pubmed: 3886132
EBioMedicine. 2019 Feb;40:349-362
pubmed: 30662000
Mol Aspects Med. 2021 Jun;79:100905
pubmed: 33010941
Front Oncol. 2022 Jun 23;12:891652
pubmed: 35814435
Transl Res. 2023 Mar;253:95-107
pubmed: 35952983
Surg Today. 1998;28(7):682-6
pubmed: 9697259
PLoS One. 2013 Apr 12;8(4):e60471
pubmed: 23593224
Immunol Res. 2023 Feb;71(1):92-104
pubmed: 36197587
Curr Cancer Drug Targets. 2021;21(2):132-152
pubmed: 33200711
Glycobiology. 2017 Jan;27(1):3-49
pubmed: 27558841